Despite all these observations, immunotherapy still has difficulty fitting into daily clinical practice for the treatment of metastatic PCa, although, dMMR and MSI-H may surely be considered as useful biomarkers to identify subsets of PCa patients who are most likely to respond to immunotherapy, along with PD-L1 status, tumor mutational burden (TMB) and other predictive factors. Here, CD274 is linked to posterior cortical atrophy.